Cargando…
Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?
The lowering of high blood pressure is supposed to protect target organs from hypertensive damage. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial was designed to compare the cardioprotective properties of three antihypertensives from different classes (lisinopril, am...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64825/ https://www.ncbi.nlm.nih.gov/pubmed/11806808 http://dx.doi.org/10.1186/cvm-2-6-257 |
_version_ | 1782120149014282240 |
---|---|
author | Gavras, Irene Gavras, Haralambos |
author_facet | Gavras, Irene Gavras, Haralambos |
author_sort | Gavras, Irene |
collection | PubMed |
description | The lowering of high blood pressure is supposed to protect target organs from hypertensive damage. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial was designed to compare the cardioprotective properties of three antihypertensives from different classes (lisinopril, amlodipine and doxazosin) with chlorthalidone. Despite effective blood pressure lowering and a favorable metabolic profile, the doxazosin arm of the trial had a significantly higher relative risk of cardiovascular disease and heart failure compared with the chlorthalidone arm. This article speculates on possible causes for this unexpected result and suggests that the culprit may be accentuation of the vascular effects of vasopressin, which are maximized under α-adrenergic blockade. These findings may have implications for the large number of older men who receive monotherapy with α-blockers for treatment of prostatic symptoms. |
format | Text |
id | pubmed-64825 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-648252002-01-25 Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? Gavras, Irene Gavras, Haralambos Curr Control Trials Cardiovasc Med Commentary The lowering of high blood pressure is supposed to protect target organs from hypertensive damage. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial was designed to compare the cardioprotective properties of three antihypertensives from different classes (lisinopril, amlodipine and doxazosin) with chlorthalidone. Despite effective blood pressure lowering and a favorable metabolic profile, the doxazosin arm of the trial had a significantly higher relative risk of cardiovascular disease and heart failure compared with the chlorthalidone arm. This article speculates on possible causes for this unexpected result and suggests that the culprit may be accentuation of the vascular effects of vasopressin, which are maximized under α-adrenergic blockade. These findings may have implications for the large number of older men who receive monotherapy with α-blockers for treatment of prostatic symptoms. BioMed Central 2001 2001-11-03 /pmc/articles/PMC64825/ /pubmed/11806808 http://dx.doi.org/10.1186/cvm-2-6-257 Text en Copyright © 2001 BioMed Central Ltd |
spellingShingle | Commentary Gavras, Irene Gavras, Haralambos Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? |
title | Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? |
title_full | Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? |
title_fullStr | Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? |
title_full_unstemmed | Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? |
title_short | Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? |
title_sort | benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the allhat? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64825/ https://www.ncbi.nlm.nih.gov/pubmed/11806808 http://dx.doi.org/10.1186/cvm-2-6-257 |
work_keys_str_mv | AT gavrasirene benefitsandsideeffectsofbloodpressureloweringtreatmentwhatwaswrongwithdoxazosinintheallhat AT gavrasharalambos benefitsandsideeffectsofbloodpressureloweringtreatmentwhatwaswrongwithdoxazosinintheallhat |